AUS
NZ
UK
CA
USA
IND
Healt
Orthocell Expands to Canada with Remplir Nerve Wrap Launch
September 30, 2025 03:19 PM AEST| By SamOrthocell (ASX:OCC) strengthens global presence with Canadian distributor for Remplir, advancing international nerve repair solutions while aligning with opportunities across ASX markets.
Starpharma & Radiopharm Transform Cancer Therapies in ASX 200
September 30, 2025 12:32 PM AEST| By SamStarpharma (ASX:SPL) teams up with Radiopharm Theranostics (ASX:RAD) to develop innovative radiotherapy assets within the ASX 200 sector.
Percheron Therapeutics Advances Oncology Pipeline with Phase II
September 30, 2025 12:22 PM AEST| By SamPercheron Therapeutics advances its HMBD-002 oncology program, securing regulatory control and preparing Phase II trials, reflecting strategic growth within the ASX 200 biotech sector.
Navigating the Storm: How Trump's Pharma Tariffs Impact ASX Healthcare Stocks
September 29, 2025 10:46 PM AEST| By SamThis article delves into the implications of U.S. President Donald Trump's 100% tariff on imported branded and patented pharmaceuticals, effective October 1, 2025.
Cochlear’s Growth Story Sparks Spotlight in the ASX 200
September 29, 2025 03:10 PM AEST| By SamCochlear (ASX:COH) shows strong capital efficiency, sustainable growth, and reduced liability reliance, reinforcing its leadership in healthcare and highlighting its importance within the ASX 200 landscape.
PolyNovo (ASX:PNV) & Key Short Selling Market Trends
September 29, 2025 11:02 AM AEST| By SamThis article delves into the dynamics of short selling in the Australian stock market, focusing on PolyNovo Limited (ASX:PNV) and its recent market movements.
CSL in Focus: What the ASX 200 Signals About Growth
September 26, 2025 03:33 PM AEST| By SamCSL Limited (ASX:CSL) draws attention in the ASX 200, with valuation debates, steady earnings growth, and contrasting market sentiment shaping its outlook within Australia’s healthcare and stock market landscape.
Tariffs Pressure CSL as ASX 200 Edges Lower
September 26, 2025 03:04 PM AEST| By SamAustralian market edged lower as (ASX:CSL) fell on US tariff news, with technology weakness weighing while ASX mining stocks and ASX dividend stocks showed resilience.
Health Stocks Face Pressure Amid ASX 200 Pharma Tariff Clouds
September 26, 2025 02:44 PM AEST| By SamHealth and retail stocks face pressure as CSL (ASX:CSL) responds to US pharma tariffs while Premier Investments (ASX:PMV) battles Smiggle misconduct concerns, sparking caution across the broader ASX market.
CSL (ASX:CSL) US Tariff Impact: Key Insights for ASX 200 Investors
September 26, 2025 01:48 PM AEST| By SamCSL (ASX:CSL) faces challenges as US tariffs on pharmaceuticals impact profits, influencing ASX 200 biotech investors and short selling trends in Australia.
INOVIQ (ASX: IIQ) Advances Ovarian Cancer Detection, Gaining Spotlight in ASX 200 Landscape
September 26, 2025 12:16 PM AEST| By SamINOVIQ (ASX:IIQ) secures worldwide rights for novel ovarian cancer biomarker technology, advancing its EXO-OC test in early cancer detection and shaping the ASX 200 healthcare landscape.
Ansell Limited (ASX:ANN) Set for Growth in ASX 200 Market
September 26, 2025 11:34 AM AEST| By SamDetailed analysis of Ansell Limited (ASX:ANN) highlights earnings growth, market positioning, and its role in the ASX 200, offering insights into investor confidence and future performance.
Why Sigma Healthcare’s (ASX:SIG) Growth Outlook Keeps It in Focus
September 25, 2025 04:10 PM AEST| By SamSigma Healthcare (ASX:SIG) remains in focus as its elevated valuation highlights growth expectations, market resilience, and its critical role in Australia’s pharmaceutical distribution sector.
Cann Group’s ASX Quotation Sparks Market Attention
September 25, 2025 02:12 PM AEST| By SamCann Group (ASX:CAN) strengthens its capital base by quoting new securities on ASX, reinforcing its role in the medicinal cannabis sector and highlighting growth within Australia’s evolving healthcare market.
Ryman Healthcare Joins ASX 200 Landscape
September 25, 2025 02:06 PM AEST| By SamRyman Healthcare (ASX:RYM) secures ASX listing, strengthening investor access, expanding retirement living sector visibility, and enhancing growth prospects across New Zealand and Australia through its dual market presence.
Recce Pharmaceuticals (ASX:RCE) Starts Phase 3 Diabetes Trial
September 25, 2025 01:20 PM AEST| By SamRecce Pharmaceuticals (ASX:RCE) launches Phase 3 trial for its R327G gel targeting diabetic foot infections, addressing global diabetes challenges and advancing innovative solutions within the ASX 200 biotech sector.
Lumos Diagnostics Lights Up Investor Focus at ASX SMIDcaps
September 24, 2025 03:24 PM AEST| By SamLumos Diagnostics (ASX:LDX) strengthens visibility with its ASX SMIDcaps 2025 Conference appearance, showcasing rapid point-of-care diagnostic innovations and reinforcing its position within the evolving ASX stock market healthcare landscape.
Race Oncology Advances RC220 Trial with Korean Approval
September 24, 2025 12:34 PM AEST| By SamRace Oncology (ASX:RAC) gains Korean approval for its RC220 Phase 1 trial, expanding its global clinical footprint and advancing oncology research with a novel chemotherapy combination.
Pro Medicus (ASX:PME): Is the ASX 200 Giant Undervalued?
September 24, 2025 10:41 AM AEST| By SamExplore how Pro Medicus (ASX:PME) drives healthcare innovation, combines stability with growth, and strengthens its position within the ASX 200 through advanced digital imaging solutions.
Is the Share Price Attractive in 2025 of this ASX Stock?
September 23, 2025 05:31 PM AEST| By SamSonic Healthcare (ASX:SHL) remains a global healthcare leader. This article explores its valuation, financial health, and position within the ASX 200 in 2025.
Advertise your brand on Kalkine Media